Monographie - Pentamidine isetionate

Última actualização :
27/11/2025

Pentamidine isetionate

estrutura química

Nomes comerciais nos diversos países

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Pentacarinat	Alemanha, Colômbia, Dinamarca, Espanha, Luxemburgo, nova Zelândia, Países Baixos, Suicia
Pentam	Estados Unidos de América
Pentamidina	Argentina, Espanha
Pentamidine isethionate	Australia, Canadá, Estados Unidos de América, Malásia

Bibliografía : Pentamidine isetionate

	tipo	publicação
36	jornal	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
73	jornal	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
198	jornal	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
275	jornal	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
337	jornal	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
424	jornal	De NC, Alam AS, Kapoor JN. Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injections. Am J Hosp Pharm 1986 ; 43: 1486-1488.
496	jornal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratório	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
1135	jornal	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1235	jornal	Leigh PH, Buddle GC. Pentamidine infusion stability. Br J Pharm Pract 1988 ; 10: 22-23.
1625	jornal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1925	jornal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
3543	Laboratório	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3559	Laboratório	Pentamidine diiséthionate (Pentacarinat®) - Résumé des caractéristiques du produit Sanofi Aventis France 2013
3560	Laboratório	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3662	Laboratório	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014

Mentions Légales